Abstract
The activity of 2 α-methyl-dihydrotestosterone propionate, was evaluated on 20 women with advanced breast cancer. The age of the patients ranged from 31 to 74 years; the compound was administered i.m. 100 mg 3 times a week, over a period of time ranging from 2 weeks to 8 months. An objective improvement was obtained in 6 patients; the mean duration of the improvement was of 5.8 months (with a maximum of 8 months). In 9 patients the lesions remained unchanged, while in 5 there was a progression of the disease during the treatment. The neoplastic lesions of breast, skin and lymph nodes appeared to be much more responsive to the treatment than the osseous and visceral lesions. The highest percentage of improvement was obtained in early postmenopausal women. The compound proved to be practically free of virilizing action, one woman only showing a marked virilization. No other notable side effects were observed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
